Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental cell therapy targets Hard-to-Treat ovarian cancers

NCT ID NCT06342986

Ongoing Disease control Sponsor: Masonic Cancer Center, University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new immune cell therapy called FT536 for people with recurrent ovarian, fallopian tube, or primary peritoneal cancer. The treatment is given directly into the abdomen after a short course of chemotherapy. Only 3 participants are enrolled, so the main goal is to check safety and see if the therapy can slow cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
FT536 (a type of immune cell therapy made from stem cells, given into the abdomen)
What this could lead to
If it works, this could point toward a new treatment option for people with recurrent gynecologic cancers that have not responded to standard therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 3 participants, so it is too soon to know if it is safe or effective. The treatment also requires chemotherapy beforehand, which has its own side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube neoplasm female reproductive organ cancer ovarian cancer ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FALLOPIAN TUBE CANCER GYNECOLOGIC CANCER OVARIAN CANCER PRIMARY PERITONEAL CAVITY CANCER

Contacts and locations

Locations

  • University of Minnesota Masonic Cancer Center

    Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.